Pulmonology

In a poster presented at the ERS Virtual Conference, investigators identify the relative rate of severe asthma exacerbations using LAMA monotherapy.

COVID-19 positive patients with COPD demonstrated a greater risk for hospitalization, ICU admission, and need for invasive mechanical ventilation compared with non-COPD patients.

In the placebo-controlled study, both treatment groups experienced similar rates of severe asthma worsening and mean time to exacerbation.

At least 2 hours of follow-up with a healthcare provider is effective at reducing healthcare use and improving the quality of life in patients with asthma.

There are several factors, both environmental and familial, that are associated with a higher risk of developing asthma and persistent wheezing.

There was no observed difference in proportion of disease progression between sildenafil combined with pirfenidone and placebo treatment groups.

Data suggests treatment with the palliative opioid does not affect PCO2 levels, suggesting it is safe in patients with moderate to severe COPD.

SalivaDirect eliminates the need for nucleic acid extraction kits, enhancing the potential capacity for testing.

Dr. Louis Kovacs discusses the risk of playing youth, college, and professional sports during the ongoing pandemic.

From immunity building to plasma research, a look at some lesser efficient practices adopted or proposed during the pandemic.

Patients with IPF and multiple comorbidities experienced similar effects from nintedanib to those with few or no comorbidities.

Tiotropium plus olodaterol is more effective for patients with COPD compared with LABA plus inhaled corticosteroids.

Results of ANDHI provide additional support on the safety and efficacy of benralizumab for patients with asthma.

Dupilumab significantly reduces exacerbation rates in patients with asthma compared to standard of care.

In a study presented virtually at ATS 2020, investigators find 15 mg of the study drug resulted in a 43% decrease in FeNO.

A new case study  assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .

In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.

A famed virologist weighs in on the country's earliest shortcomings—and how they can still be resolved today.

A one-time intramuscular dose of the investigative drug was linked to reduced medical attention and hospitalizations related to RSV.

New findings suggest differing chronic lung diseases are associated with varying risk factors among COVID-19 patients.

World-leading virologist and AIDS researcher David Ho, MD, joins the inaugural podcast episode.

A discussion on how thromboembolism research and care could benefit from progression in diagnostics.

Patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less had an adjusted hazard ratio for mortality of 1.71.

The approval are based on a pair of recent phase 3 trials showing the safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate.

Until more is known about long-term cardiac mechanisms behind MIS-C, providers could consider following Kawasaki disease guidelines for follow-up care